Bicycle Therapeutics (BCYC) Common Equity (2018 - 2026)

Bicycle Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $554.3 million for Q1 2026.

• Quarterly Common Equity fell 25.13% year-over-year to $554.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $554.3 million (down 25.13% YoY) and the FY2025 annual result came in at $610.0 million, down 23.09% from the prior year.
• Common Equity was $554.3 million for Q1 2026 at Bicycle Therapeutics, down from $610.0 million in the prior quarter.
• Across five years, Common Equity topped out at $873.8 million in Q2 2024 and bottomed at $220.1 million in Q2 2023.
• A 5-year average of $499.9 million and a median of $416.0 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity fell 29.32% — and 2024, when it surged 297.01%.
• Bicycle Therapeutics' Common Equity stood at $270.8 million in 2022, then jumped by 36.98% to $370.9 million in 2023, then jumped by 113.8% to $793.1 million in 2024, then retreated by 23.09% to $610.0 million in 2025, then dropped by 9.12% to $554.3 million in 2026.
• Business Quant data shows BCYC's Common Equity at $554.3 million in Q1 2026, $610.0 million in Q4 2025, and $618.5 million in Q3 2025.